JP2025507678A - Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法 - Google Patents

Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法 Download PDF

Info

Publication number
JP2025507678A
JP2025507678A JP2024550195A JP2024550195A JP2025507678A JP 2025507678 A JP2025507678 A JP 2025507678A JP 2024550195 A JP2024550195 A JP 2024550195A JP 2024550195 A JP2024550195 A JP 2024550195A JP 2025507678 A JP2025507678 A JP 2025507678A
Authority
JP
Japan
Prior art keywords
cells
car
subject
optionally
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507678A5 (enExample
Inventor
ファン シャオフー
シェクター ジョーダン
パコー リダ
ハーシュマン マイケル
Original Assignee
ヤンセン バイオテック， インク．
ナンジン レジェンド バイオテック シーオー．， エルティーディー．
レジェンド バイオテック ユーエスエー インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテック， インク．, ナンジン レジェンド バイオテック シーオー．， エルティーディー．, レジェンド バイオテック ユーエスエー インク． filed Critical ヤンセン バイオテック， インク．
Publication of JP2025507678A publication Critical patent/JP2025507678A/ja
Publication of JP2025507678A5 publication Critical patent/JP2025507678A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
JP2024550195A 2022-02-28 2023-02-27 Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法 Pending JP2025507678A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263314968P 2022-02-28 2022-02-28
US63/314,968 2022-02-28
PCT/US2023/063352 WO2023164695A2 (en) 2022-02-28 2023-02-27 Bcma-targeted car-t cell therapy for multiple myeloma

Publications (2)

Publication Number Publication Date
JP2025507678A true JP2025507678A (ja) 2025-03-21
JP2025507678A5 JP2025507678A5 (enExample) 2026-04-28

Family

ID=87762032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550195A Pending JP2025507678A (ja) 2022-02-28 2023-02-27 Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法

Country Status (9)

Country Link
US (1) US20230270786A1 (enExample)
EP (1) EP4486372A2 (enExample)
JP (1) JP2025507678A (enExample)
KR (1) KR20240158888A (enExample)
CN (1) CN118900698A (enExample)
AU (1) AU2023223523A1 (enExample)
CA (1) CA3252674A1 (enExample)
MX (1) MX2024010527A (enExample)
WO (1) WO2023164695A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114929747A (zh) 2019-11-05 2022-08-19 詹森生物科技公司 多发性骨髓瘤的靶向bcma的car-t细胞疗法
GR1010884B (el) * 2023-08-30 2025-02-19 Janssen Biotech, Inc., Θεραπεια τ κυτταρων με χιμαιρικο υποδοχεα αντιγονου (car) με στοχευμενο αντιγονο ωριμανσης των β κυτταρων (bcma) για πολλαπλο μυελωμα
WO2025170902A1 (en) * 2024-02-05 2025-08-14 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
US20250339527A1 (en) * 2024-03-12 2025-11-06 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
NZ579010A (en) 2007-02-20 2012-03-30 Anaptysbio Inc Somatic hypermutation systems
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
KR102512934B1 (ko) 2016-08-10 2023-03-23 레전드 바이오테크 아일랜드 리미티드 Bcma를 표적으로 하는 키메라 항원 수용체 및 이들의 이용 방법

Also Published As

Publication number Publication date
CN118900698A (zh) 2024-11-05
EP4486372A2 (en) 2025-01-08
US20230270786A1 (en) 2023-08-31
MX2024010527A (es) 2024-12-06
AU2023223523A1 (en) 2024-09-26
WO2023164695A3 (en) 2023-10-05
WO2023164695A2 (en) 2023-08-31
KR20240158888A (ko) 2024-11-05
CA3252674A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
US20230270786A1 (en) Bcma-targeted car-t cell therapy for multiple myeloma
JP2023551877A (ja) Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法
KR20240117530A (ko) 다발성 골수종을 위한 bcma를 표적으로 하는 car-t 세포 요법
KR20220100612A (ko) 다발성 골수종의 bcma-표적화 car-t 세포 요법
DK202530747A1 (en) Bcma-targeted car-t cell therapy for multiple myeloma
US20250339527A1 (en) Bcma-targeted car-t cell therapy for multiple myeloma
US20250269024A1 (en) Bcma-targeted car-t cell therapy for multiple myeloma
TR2025015426T2 (tr) Multi̇pl mi̇yeloma yöneli̇k bcma hedefli̇ car-t hücre terapi̇si̇
GR1010884B (el) Θεραπεια τ κυτταρων με χιμαιρικο υποδοχεα αντιγονου (car) με στοχευμενο αντιγονο ωριμανσης των β κυτταρων (bcma) για πολλαπλο μυελωμα
SI26522A (sl) Odmerek celic T za uporabo v postopku zdravljenja multiplega mieloma (diseminiranega plazmacitoma) pri osebku

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260224

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20260415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260417